FREHY — Fresh2 Share News
0.000.00%
Last trade - 00:00FinancialsSpeculativeMicro Cap
- $0.00m
- $2.69m
- CNY12.04m
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022
U.S. STOCKS ON THE MOVE-Lilium, Pfizer Inc, Lazydays Holdings
U.S. STOCKS ON THE MOVE-Affirm Holdings, Volt Information, Chevron Corp
U.S. STOCKS ON THE MOVE-Southwest Gas, JD.com, Ford
U.S. STOCKS ON THE MOVE-Tesla, Apple, ExxonMobil
AnPac Bio slumps on Nasdaq notice
Brief: Anpac Bio-Medical Sciences Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Changwei System Technology Receives Approval From Board To Explore Strategic Alternatives
Brief: Anpac Bio Files Cda Device For Breakthrough Medical Device Designation Request With The FDA
Brief: Anpac Bio Receives Nasdaq Notification Regarding Minimum Market Value Of Publicly Held Shares Deficiency
Brief: AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests
Brief: Anpac Bio Announces Pricing Of Approximately $2.9 Million Underwritten Public Offering Of American Depositary Shares
Brief: AnPac Bio Study Shows Strong Correlation Between CDA Score And Risk Of Cancer And Diseases
Brief: AnPac Bio Receives Nasdaq Notification Regarding Minimum Market Value Of Listed Securities Deficiency
Brief: AnPac Bio Increases Ownership Percentage Of Its Subsidiary Anpai Healthcare From 20% To 60%
Brief: Anpac Bio Successfully Completes Major Preclinical Study, Files With NMPA For Registration Testing Of Its Multi-Cancer Cda Device